Non–small cell lung cancer: epidemiology, screening, diagnosis, and treatment
N Duma, R Santana-Davila, JR Molina - Mayo Clinic Proceedings, 2019 - Elsevier
Lung cancer remains the leading cause of cancer deaths in the United States. In the past
decade, significant advances have been made in the science of non–small cell lung cancer (…
decade, significant advances have been made in the science of non–small cell lung cancer (…
Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology
…, C Rusthoven, J Sands, R Santana-Davila… - Journal of the National …, 2021 - jnccn.org
… Rafael Santana-Davila Rafael Santana-Davila Fred Hutchinson Cancer Research Center/Seattle
Cancer Care Alliance… Search for other papers by Rafael Santana-Davila in …
Cancer Care Alliance… Search for other papers by Rafael Santana-Davila in …
[HTML][HTML] A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache
JL Jackson, E Cogbill, R Santana-Davila, C Eldredge… - PloS one, 2015 - journals.plos.org
Objective To compare the effectiveness and side effects of migraine prophylactic medications.
Design We performed a network meta-analysis. Data were extracted independently in …
Design We performed a network meta-analysis. Data were extracted independently in …
Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase …
…, B Besse, L Greillier, R Santana-Davila… - Clinical Cancer …, 2019 - AACR
Purpose: Although extensive-stage small-cell lung cancer (SCLC) is highly responsive to
first-line therapy, virtually all patients develop resistance with short survival. Rovalpituzumab …
first-line therapy, virtually all patients develop resistance with short survival. Rovalpituzumab …
NCCN guidelines insights: small cell lung cancer, version 2.2018
…, C Rusthoven, J Sands, R Santana-Davila… - Journal of the National …, 2018 - jnccn.org
The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease
management. These NCCN Guidelines Insights focus on recent updates to the NCCN …
management. These NCCN Guidelines Insights focus on recent updates to the NCCN …
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas …
RS Herbst, HT Arkenau, R Santana-Davila… - The Lancet …, 2019 - thelancet.com
Background Pre-clinical and clinical evidence suggests that simultaneous blockade of
VEGF receptor-2 (VEGFR-2) and PD-1 or PD-L1 enhances antigen-specific T-cell migration, …
VEGF receptor-2 (VEGFR-2) and PD-1 or PD-L1 enhances antigen-specific T-cell migration, …
[HTML][HTML] Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
…, HL Kindler, N Niknafs, T Purcell, R Santana-Davila… - Nature medicine, 2021 - nature.com
Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent approval
of combination immune checkpoint blockade. Here we report the results of the phase 2 …
of combination immune checkpoint blockade. Here we report the results of the phase 2 …
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma
…, JM Winkler, E Blood, MM Oken, R Santana-Dávila… - Blood, 2003 - ashpublications.org
Aneuploid is ubiquitous in multiple myeloma (MM), and 4 cytogenetic subcategories are
recognized: hypodiploid (associated with a shorter survival), pseudodiploid, hyperdiploid, and …
recognized: hypodiploid (associated with a shorter survival), pseudodiploid, hyperdiploid, and …
[HTML][HTML] Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non–small-cell lung cancer: An analysis of Veterans Health …
R Santana-Davila, K Devisetty, A Szabo… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
Purpose The optimal chemotherapy regimen to use with radiotherapy in stage III non–small-cell
lung cancer is unknown. Here, we compare the outcome of patents treated within the …
lung cancer is unknown. Here, we compare the outcome of patents treated within the …
Addition of metformin to concurrent chemoradiation in patients with locally advanced non–small cell lung cancer: The NRG-LU001 phase 2 randomized clinical trial
Importance Non–small cell lung cancer (NSCLC) has relatively poor outcomes. Metformin
has significant data supporting its use as an antineoplastic agent. Objective To compare …
has significant data supporting its use as an antineoplastic agent. Objective To compare …